A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies

被引：0
|
作者：
Chia, S. K.
Chi, K. N.
Kollmannsberger, C.
Paton, K.
Bhagat, K.
D'Aloisio, S.
Das-Gupta, A.
Kletzl, H.
Zwanziger, E.
Gelmon, K.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC, Canada
[2] Vancouver Gen Hosp, Vancouver, BC, Canada
[3] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
    Tan, A. R.
    Dowlati, A.
    Stein, M. N.
    Jones, S. F.
    Infante, J. R.
    Bendell, J.
    Kane, M. P.
    Levinson, K. T.
    Suttle, A. B.
    Burris, H. A., III
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2647 - 2654
  • [22] Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
    A R Tan
    A Dowlati
    M N Stein
    S F Jones
    J R Infante
    J Bendell
    M P Kane
    K T Levinson
    A B Suttle
    H A Burris III
    British Journal of Cancer, 2014, 110 : 2647 - 2654
  • [23] Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Alain Mita
    John Sarantopoulos
    Chris H. Takimoto
    Eric K. Rowinsky
    Ofelia Romero
    Patrizia Angiuli
    Cecilia Allievi
    Amy Eisenfeld
    Claire F. Verschraegen
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 287 - 295
  • [24] A phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of ES-285, a novel marine anti-cancer agent, in patients with advanced solid tumours.
    Baird, RD
    Planting, AS
    Reid, AH
    Kitzen, J
    Reade, S
    Escolar, L
    de las Heras, B
    Fong, P
    Molife, R
    Shaw, H
    Eskens, F
    de Bono, JS
    Verweij, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9055S - 9056S
  • [25] A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies
    Wang, H.
    Markman, B.
    de Souza, P.
    Dees, E. C.
    Gangadhar, T. C.
    Piha-Paul, S. A.
    Zamboni, W. C.
    Murphy, C.
    Senderowicz, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
    Stewart, DJ
    Donehower, RC
    Eisenhauer, EA
    Wainman, N
    Shah, AK
    Bonfils, C
    MacLeod, AR
    Besterman, JM
    Reid, GK
    ANNALS OF ONCOLOGY, 2003, 14 (05) : 766 - 774
  • [27] Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.
    Geoerger, Birgit
    Morland, Bruce
    Jimenez, Irene
    Frappaz, Didier
    Pearson, Andrew D. J.
    Vassal, Gilles
    Maeda, Patricia
    Kincaide, Jasmine
    Mueller, Udo
    Schlief, Sarah
    Cleton, Adriaan
    Chassot-Agostinho, Andrea
    Marshall, Lynley V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
    Chiorean, E. Gabriela
    Porter, Jennifer M.
    Foster, Anne E.
    Al Omari, Amal S. H.
    Yoder, Christy A.
    Fife, Karen L.
    Strother, R. Matthew
    Murry, Daryl J.
    Yu, Menggang
    Jones, David R.
    Sweeney, ChristopherJ.
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1131 - 1137
  • [29] Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
    Forouzesh, Bahram
    Hidalgo, Manuel
    Chu, Quincy
    Mita, Alain
    Mita, Monica
    Schwartz, Garry
    Jimeno, Jose
    Gomez, Javier
    Alfaro, Vicente
    Lebedinsky, Claudia
    Zintl, Patrik
    Rowinsky, Eric K.
    CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3591 - 3599
  • [30] A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer
    Odunsi, K.
    Ghamande, S.
    Macfee, M.
    Yu, A. Yin Chieh
    Lele, S. B.
    Rodabaugh, K. J.
    Thomas, B.
    Zamboni, W. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345